15
Participants
Start Date
October 1, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
Sodium Butyrate (NaBu)
Participants will self-administer Sodium Butyrate (NaBu) daily for 12 weeks. The study aims to evaluate the effect of NaBu on menstrual symptoms by comparing symptom severity before and during the intervention. Participants will maintain an electronic diary (eDiary) to record their daily symptom severity, which will be used to assess changes over time. Regular follow-ups will be conducted to monitor progress and address any side effects or concerns.
RECRUITING
Northwestern University - Northwestern Medicine, Lavin Family Pavilion, Chicago
Magdy Milad, MD
OTHER